JANX · Janux Therapeutics, Inc.
$16.54
-0.39 (-2.30%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$996.53M
Shares
61.14M
Volume · Oct 5
533.74K
Avg daily vol (3M)
842.89K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.54
Open$16.93
Day$16.13–16.95
52W close$12.18–34.74
Avg vol 30d937K
Short int5.9M · 9.6% float · 5.9d
Short vol64%
Last earningsDec 1, 2025
DataJun 2021–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$24.00M
Trailing 12 months
Net income (TTM)
−$102.59M
Trailing 12 months
Revenue growth YoY
-5.6%
Year over year
Operating margin
-598.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-4.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$970.91M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.7%
Year over year · more shares
Price change (1Y)
-27.4%
Trailing year
Short interest
9.6%
Latest settlement · 5.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+10%
above
Price vs 50-day avg
−3%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
19%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−18%
trailing
6-month return
+9%
trailing
YTD return
+20%
this year
Relative strength
−3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $15 — 50d above 200d
Institutional flow
Accumulating
1 of 199 funds reported for Sep 30 · net +1.5K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
9.64% of float · ▼ -2.8% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
199 holders — mid 3-yr range
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
−6%
Y/Y
EPS growth
−43%
Y/Y
Free cash flow
$-83.3M
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+10%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
19%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $17 › 200d $15 — 50d above 200d
Institutional flow
Accumulating
1 of 199 funds reported for Sep 30 · net +1.5K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
9.64% of float · ▼ -2.8% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
199 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $12
Now $17 · 19%
Range high $35
vs 200-day avg +10%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash and cash equivalents and short-term investments | $970.9M | second quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JANX
this stock
Janux Therapeutics, Inc.
|
$996.53M | +19.9% | -5.6% | — | 9.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JANX | -0.2% | -18.3% | +8.5% | -4.3% | +19.9% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -1.4% | -18.9% | -3.0% | -5.9% | +6.2% |